This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • FDA grants priority review of sutimlimab, potentia...
News

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis for cold agglutinin disease.- Sanofi

Read time: 1 mins
Last updated:18th May 2020
Published:15th May 2020
Condition: Cold Agglutinin Disease
Type: drug
Register now for full access to medthority.com